Does the media favor ABUS or TARA?

In the previous week, Arbutus Biopharma had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Arbutus Biopharma and 2 mentions for Protara Therapeutics. Arbutus Biopharma's average media sentiment score of 0.80 beat Protara Therapeutics' score of -0.10 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ANNX or TARA?

Annexon is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A

Is ANNX or TARA more profitable?

Protara Therapeutics' return on equity of -41.72% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Protara Therapeutics N/A -41.72% -38.78%

Does the media favor ANNX or TARA?

In the previous week, Annexon had 4 more articles in the media than Protara Therapeutics. MarketBeat recorded 6 mentions for Annexon and 2 mentions for Protara Therapeutics. Annexon's average media sentiment score of 0.51 beat Protara Therapeutics' score of -0.10 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, SLDB or TARA?

Solid Biosciences is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A

Is SLDB or TARA more profitable?

Protara Therapeutics' return on equity of -41.72% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Protara Therapeutics N/A -41.72% -38.78%

Does the media favor SLDB or TARA?

In the previous week, Solid Biosciences had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 2 mentions for Protara Therapeutics. Solid Biosciences' average media sentiment score of 0.82 beat Protara Therapeutics' score of -0.10 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, TARA or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A Design Therapeutics N/A N/A -$69.79M -$1.18 N/A

Is TARA or DSGN more profitable?

Design Therapeutics' return on equity of -34.03% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Design Therapeutics N/A -34.03% -32.05%

Does the media refer more to TARA or KURA?

In the previous week, Kura Oncology had 15 more articles in the media than Protara Therapeutics. MarketBeat recorded 17 mentions for Kura Oncology and 2 mentions for Protara Therapeutics. Kura Oncology's average media sentiment score of 0.79 beat Protara Therapeutics' score of -0.10 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kura Oncology 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protara Therapeutics (TARA) Competitors

$3.85 -0.05 (-1.28%)

As of 08/21/2026 04:00 PM Eastern

Compare

TARA vs. ABUS, ANNX, SLDB, DSGN, and KURA

Should you buy Protara Therapeutics stock or one of its competitors? Protara Therapeutics's main competitors and comparable companies include Arbutus Biopharma (ABUS), Annexon (ANNX), Solid Biosciences (SLDB), Design Therapeutics (DSGN), and Kura Oncology (KURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protara Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arbutus Biopharma had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Arbutus Biopharma and 2 mentions for Protara Therapeutics. Arbutus Biopharma's average media sentiment score of 0.80 beat Protara Therapeutics' score of -0.10 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Protara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arbutus Biopharma has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	73.21	-$33.50M	$0.79	6.59
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential downside of 4.03%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 581.82%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Arbutus Biopharma has a net margin of 84.22% compared to Protara Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Protara Therapeutics	N/A	-41.72%	-38.78%

Arbutus Biopharma has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Arbutus Biopharma beats Protara Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Annexon has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Protara Therapeutics' return on equity of -41.72% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Protara Therapeutics	N/A	-41.72%	-38.78%

Annexon is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

In the previous week, Annexon had 4 more articles in the media than Protara Therapeutics. MarketBeat recorded 6 mentions for Annexon and 2 mentions for Protara Therapeutics. Annexon's average media sentiment score of 0.51 beat Protara Therapeutics' score of -0.10 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Annexon currently has a consensus target price of $15.33, indicating a potential upside of 202.43%. Protara Therapeutics has a consensus target price of $26.25, indicating a potential upside of 581.82%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

38.1% of Protara Therapeutics shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Protara Therapeutics beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Solid Biosciences had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 2 mentions for Protara Therapeutics. Solid Biosciences' average media sentiment score of 0.82 beat Protara Therapeutics' score of -0.10 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Solid Biosciences presently has a consensus price target of $17.40, indicating a potential upside of 87.10%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 581.82%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Solid Biosciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Solid Biosciences is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Protara Therapeutics' return on equity of -41.72% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Protara Therapeutics	N/A	-41.72%	-38.78%

Summary

Protara Therapeutics beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Design Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Protara Therapeutics currently has a consensus price target of $26.25, suggesting a potential upside of 581.82%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 10.07%. Given Protara Therapeutics' higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics' return on equity of -34.03% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Design Therapeutics	N/A	-34.03%	-32.05%

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Design Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

In the previous week, Protara Therapeutics had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 2 mentions for Protara Therapeutics and 0 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.00 beat Protara Therapeutics' score of -0.10 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Design Therapeutics	Neutral

Protara Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Summary

Design Therapeutics beats Protara Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Kura Oncology?

Protara Therapeutics (NASDAQ:TARA) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Kura Oncology had 15 more articles in the media than Protara Therapeutics. MarketBeat recorded 17 mentions for Kura Oncology and 2 mentions for Protara Therapeutics. Kura Oncology's average media sentiment score of 0.79 beat Protara Therapeutics' score of -0.10 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kura Oncology	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Kura Oncology	$67.48M	15.67	-$278.67M	-$3.37	N/A

Protara Therapeutics currently has a consensus price target of $26.25, suggesting a potential upside of 581.82%. Kura Oncology has a consensus price target of $25.62, suggesting a potential upside of 115.44%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Protara Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Protara Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Protara Therapeutics' return on equity of -41.72% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Kura Oncology	-384.30%	-207.18%	-45.17%

38.1% of Protara Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Protara Therapeutics beats Kura Oncology on 10 of the 14 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$227.52M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-2.85	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.41	16.80	13.05	6.20
Net Income	-$57.44M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-3.02%	3.29%	2.09%	0.08%
1 Month Performance	-4.70%	8.23%	6.64%	3.88%
1 Year Performance	23.79%	55.05%	25.02%	16.98%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	1.6161 of 5 stars	$3.85 -1.3%	$26.25 +581.8%	+23.8%	$227.52M	N/A	N/A	30
ABUS Arbutus Biopharma	1.272 of 5 stars	$4.59 -0.9%	$5.00 +8.9%	+45.1%	$914.60M	$14.08M	5.53	90	News Coverage Buyback Announcement Gap Up
ANNX Annexon	2.9278 of 5 stars	$5.39 -0.4%	$15.33 +184.5%	+119.5%	$886.39M	N/A	N/A	60
SLDB Solid Biosciences	2.4061 of 5 stars	$8.56 +2.0%	$17.11 +99.9%	+56.8%	$882M	N/A	N/A	100	News Coverage Positive News Analyst Forecast
DSGN Design Therapeutics	0.7597 of 5 stars	$14.33 +2.4%	$16.50 +15.1%	+185.0%	$875.52M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. ABUS, ANNX, SLDB, DSGN, and KURA

How does Protara Therapeutics compare to Arbutus Biopharma?

Summary

How does Protara Therapeutics compare to Annexon?

Summary

How does Protara Therapeutics compare to Solid Biosciences?

Summary

How does Protara Therapeutics compare to Design Therapeutics?

Summary

How does Protara Therapeutics compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. ABUS, ANNX, SLDB, DSGN, and KURA

How does Protara Therapeutics compare to Arbutus Biopharma?

Do insiders and institutionals believe in ABUS or TARA?

Does the media favor ABUS or TARA?

Which has preferable earnings & valuation, ABUS or TARA?

Do analysts recommend ABUS or TARA?

Is ABUS or TARA more profitable?

Which has more volatility & risk, ABUS or TARA?

Summary

How does Protara Therapeutics compare to Annexon?

Which has more volatility and risk, ANNX or TARA?

Is ANNX or TARA more profitable?

Which has stronger valuation & earnings, ANNX or TARA?

Does the media favor ANNX or TARA?

Do analysts recommend ANNX or TARA?

Do institutionals & insiders believe in ANNX or TARA?

Summary

How does Protara Therapeutics compare to Solid Biosciences?

Does the media favor SLDB or TARA?

Do analysts recommend SLDB or TARA?

Which has more risk & volatility, SLDB or TARA?

Which has better earnings and valuation, SLDB or TARA?

Do institutionals and insiders believe in SLDB or TARA?

Is SLDB or TARA more profitable?

Summary

How does Protara Therapeutics compare to Design Therapeutics?

Do analysts prefer TARA or DSGN?

Is TARA or DSGN more profitable?

Do insiders & institutionals have more ownership in TARA or DSGN?

Which has better valuation & earnings, TARA or DSGN?

Does the media prefer TARA or DSGN?

Which has more risk and volatility, TARA or DSGN?

Summary

How does Protara Therapeutics compare to Kura Oncology?

Does the media refer more to TARA or KURA?

Which has stronger valuation and earnings, TARA or KURA?

Do analysts prefer TARA or KURA?

Which has more volatility and risk, TARA or KURA?

Is TARA or KURA more profitable?

Do institutionals and insiders hold more shares of TARA or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools